Metastatic breast cancer (MBC), also known as stage 4 breast cancer, occurs when cancer cells spread from the original tumor in the breast to distant parts of the body, such as the bones, liver, lungs, or brain.

Metastatic Breast Cancer Therapy: Understanding Your Treatment Options

Metastatic breast cancer (MBC), also known as stage 4 breast cancer, occurs when cancer cells spread from the original tumor in the breast to distant parts of the body, such as the bones, liver, lungs, or brain. While MBC is generally not considered curable, advancements in metastatic breast cancer therapy have significantly improved outcomes, focusing on controlling the disease, extending life, and maintaining a good quality of life.

What is Metastatic Breast Cancer?

Unlike early-stage breast cancer, which is confined to the breast or nearby lymph nodes, metastatic breast cancer involves the spread of cancer cells through the bloodstream or lymphatic system to other organs. This diagnosis can be challenging, but understanding the disease and available treatments is the first step in managing it effectively.

Goals of Therapy for Metastatic Breast Cancer

The primary goals of metastatic breast cancer therapy are to:

• Control the growth and spread of cancer cells.


• Alleviate symptoms caused by the cancer.


• Improve or maintain the patient's quality of life.


• Extend overall survival.

Treatment plans are highly individualized, considering the cancer's characteristics, previous treatments, and the patient's overall health and preferences.

Personalized Approach to Treatment

Therapy for metastatic breast cancer is tailored based on several factors, including:

• Hormone Receptor Status: Whether the cancer cells have estrogen receptors (ER+) or progesterone receptors (PR+).


• HER2 Status: Whether the cancer cells overexpress the human epidermal growth factor receptor 2 protein (HER2+).


• Triple-Negative Breast Cancer (TNBC): Cancers that are ER-, PR-, and HER2-negative.


• Genomic Mutations: Specific genetic changes in the tumor, such as PIK3CA or BRCA mutations.


• Location of Metastases: The organs affected by the spread.


• Prior Treatments: What therapies have been used before and how effective they were.

Key Treatment Modalities for MBC

Hormone Therapy

For hormone receptor-positive (ER+/PR+) metastatic breast cancer, hormone therapy (also known as endocrine therapy) is often the first line of treatment. These therapies work by blocking hormones from reaching cancer cells or by reducing the body's production of hormones. Options include:

• Selective estrogen receptor modulators (SERMs) like tamoxifen.


• Aromatase inhibitors (AIs) like anastrozole, letrozole, and exemestane.


• Estrogen receptor downregulators (ERDs) like fulvestrant.


• Combinations with CDK4/6 inhibitors, PI3K inhibitors, or mTOR inhibitors.

HER2-Targeted Therapy

For HER2-positive MBC, treatments specifically target the HER2 protein on cancer cells. These are highly effective and can include:

• Monoclonal antibodies like trastuzumab (Herceptin) and pertuzumab (Perjeta).


• Antibody-drug conjugates (ADCs) like trastuzumab emtansine (Kadcyla) and trastuzumab deruxtecan (Enhertu).


• Tyrosine kinase inhibitors (TKIs) like lapatinib (Tykerb), neratinib (Nerlynx), and tucatinib (Tukysa).

Chemotherapy

Chemotherapy uses drugs to kill rapidly dividing cancer cells throughout the body. It is often used for triple-negative MBC, HER2-positive MBC (often in combination with targeted therapy), or hormone receptor-positive MBC when hormone therapy is no longer effective. Various chemotherapy drugs are available, administered intravenously or orally, often in cycles.

Immunotherapy

Immunotherapy harnesses the body's own immune system to fight cancer. For certain types of metastatic breast cancer, particularly triple-negative breast cancer with specific PD-L1 expression, immunotherapy drugs like pembrolizumab (Keytruda) can be used, often in combination with chemotherapy.

Other Targeted Therapies

Beyond HER2-targeted therapies, other targeted treatments focus on specific molecular pathways that drive cancer growth:

• CDK4/6 Inhibitors: Drugs like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) are used in combination with hormone therapy for HR+/HER2- MBC.


• PARP Inhibitors: For patients with germline BRCA1/2 mutations, drugs like olaparib (Lynparza) and talazoparib (Talzenna) may be an option.


• PI3K Inhibitors: Alpelisib (Piqray) is approved for HR+/HER2- MBC with a PIK3CA mutation.

Bone-Targeted Therapies

When breast cancer spreads to the bones, treatments like bisphosphonates (e.g., zoledronic acid) or denosumab (Xgeva) are used to strengthen bones, reduce pain, and prevent bone-related complications such as fractures or spinal cord compression.

Localized Treatments

While systemic therapies treat cancer throughout the body, localized treatments may be used to manage specific metastatic sites:

• Radiation Therapy: Used to relieve pain, shrink tumors in specific areas (like bone or brain), or prevent fractures.


• Surgery: Rarely used for metastatic sites, but may be considered in very specific circumstances to remove a single metastasis or manage complications.

The Role of Clinical Trials

Clinical trials offer access to investigational treatments that are not yet widely available. For many patients with metastatic breast cancer, participating in a clinical trial can provide new therapeutic options and contribute to advancing cancer research.

Managing Side Effects and Supporting Quality of Life

Managing side effects is a crucial aspect of metastatic breast cancer therapy. A multidisciplinary care team, including oncologists, palliative care specialists, pain management specialists, and supportive care professionals, works to alleviate symptoms and improve overall well-being. This can involve medication for pain, nausea, fatigue, or other treatment-related side effects, as well as nutritional counseling, physical therapy, and emotional support.

Conclusion: A Multidisciplinary Approach

Living with metastatic breast cancer requires ongoing management and a comprehensive approach. A dedicated team of healthcare professionals will work with you to develop a personalized metastatic breast cancer therapy plan that optimizes treatment effectiveness while prioritizing your quality of life. Continuous communication with your medical team is essential to navigate the complexities of MBC treatment and make informed decisions about your care.